Literature DB >> 7855326

Immune manifestations of inflammatory muscle disease.

I N Targoff1.   

Abstract

Evidence of autoimmune muscle injury and of systemic autoimmunity is seen in PM and DM. In typical PM, a cell-mediated attack on muscle fibers by CD8+ cytotoxic T cells predominates, directed at an unknown antigen. In DM, vascular injury is prominent, with loss of muscle capillaries and ischemic muscle damage, apparently mediated by local complement activation in small muscle vessels. Although humoral immunity seems more important in the pathogenesis of DM, serum autoantibodies are commonly found in both forms. About one third of patients have MSAs, whereas others have less specific antibodies such as anti-U1RNP, often associated with overlap syndromes involving myositis. MSAs are mutually exclusive and define characteristic clinical subgroups. Antibodies to five of the aminoacyl-tRNA synthetases are each associated with an "antisynthetase syndrome" marked by myositis, ILD, arthritis, and other features, but individual patients have only a single antisynthetase. Rare autoantibodies to certain translation factors may be associated with a similar syndrome. Anti-SRP is commonly associated with severe, acute, resistant myositis, whereas anti-Mi-2, the only MSA directed at a nuclear protein, is specifically associated with DM. Patients with anti-PM-Scl commonly have an overlap syndrome of PM/DM and SSc. Recent studies have recognized other antibodies in PM and DM, including antibody to endothelial cells, heat shock proteins, and, in a high proportion of patients, a 56-kd component of a ribonucleoprotein particle. The MSAs and their antigens are being characterized in detail. To date, data suggest similarity of predominant epitopes between different patients and a tendency toward conformational epitopes. It is not known if the recognized autoantibodies participate in tissue injury or pathogenetic processes, but production of the MSAs appears to be linked to etiologic factors and can be a clue to understanding the disease. Although these autoimmune responses are becoming better defined, the inciting events leading to generation of these responses and development of PM and DM remain unknown.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855326

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  12 in total

1.  Autoantibody profiles in the sera of European patients with myositis.

Authors:  R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

2.  An unspecific immunostimulating agent and juvenile dermatomyositis: enhanced T-cell proliferation and reverse immunosuppression as a severe adverse drug reaction.

Authors:  Gerd M Lackmann; Jenny Ndagijimana; Tim Niehues
Journal:  Eur J Pediatr       Date:  2003-08-07       Impact factor: 3.183

Review 3.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

4.  Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies.

Authors:  H F Becker; Y Corda; M B Mathews; J L Fourrey; H Grosjean
Journal:  RNA       Date:  1999-07       Impact factor: 4.942

Review 5.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

6.  Dermatomyositis and Polymyositis.

Authors:  Hannah R. Briemberg; Anthony A. Amato
Journal:  Curr Treat Options Neurol       Date:  2003-09       Impact factor: 3.598

Review 7.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

8.  Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.

Authors:  E Feist; T Dörner; U Kuckelkorn; G Schmidtke; B Micheel; F Hiepe; G R Burmester; P M Kloetzel
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

9.  Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome.

Authors:  Seo-Hyun Kim; I-Nae Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-07-01

10.  Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy.

Authors:  Hajime Sasano; Eri Hagiwara; Hideya Kitamura; Yasunori Enomoto; Norikazu Matsuo; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Tae Iwasawa; Shinji Sato; Yasuo Suzuki; Tamiko Takemura; Takashi Ogura
Journal:  BMC Pulm Med       Date:  2016-12-01       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.